In order to read Genmab's Interim Report for the 9 months ended September 30, 2007 please see the attached file.
Recommended Reading
-
Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The...
Read More -
August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 Highlights Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with...
Read More